96-30-0

Basic information

• Product Name: 2-Chloro-N-methylacetamide
• Synonyms: OTAVA-BB BB7020410071;N-METHYL-2-CHLOROACETAMIDE;2-chloro-n-methyl-acetamid;Acetamide, 2-chloro-N-methyl-;alpha-Chloro-N-methylacetamide;N-Methylchloroacetamide;USAF do-35;usafdo-35
• CAS NO: 96-30-0
• Molecular Formula: C₃H₆ClNO
• Molecular Weight: 107.54
• EINECS: 202-497-1
• Product Categories: Acids and Derivatives
• Mol File: 96-30-0.mol
• Article Data: 26

Chemical Properties

• Melting Point: 38-40°C
• Boiling Point: 112-115°C 20mm
• Flash Point: 110 °C
• Appearance: brown or black
• Density: 1.127 g/cm³
• Vapor Pressure: 0.0138mmHg at 25°C
• Refractive Index: 1.425
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 14.38±0.46(Predicted)
• CAS DataBase Reference: 2-Chloro-N-methylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-N-methylacetamide(96-30-0)
• EPA Substance Registry System: 2-Chloro-N-methylacetamide(96-30-0)

Safety Data

• Statements: 36/37/38-43-22
• Safety Statements: 26-36/37/39-36/37-24
• RTECS: AB5775000
• HazardClass: IRRITANT
• Hazardous Substances Data: 96-30-0(Hazardous Substances Data)

Usage

Description

2-Chloro-N-methylacetamide is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals. It is characterized by its chloro and methyl groups attached to an amide functional group, which contributes to its reactivity and potential applications in medicinal chemistry.

Uses

Used in Pharmaceutical Industry:
2-Chloro-N-methylacetamide is used as a chemical intermediate for the preparation of piperidinylamino pyrrolopyrimidines. These compounds are selective Janus kinase inhibitors, which are important for the treatment of autoimmune diseases and organ transplant rejection. The ability of 2-Chloro-N-methylacetamide to be incorporated into these therapeutic agents highlights its significance in the development of targeted treatments for various medical conditions.

InChI:InChI=1/C3H6ClNO/c1-5-3(6)2-4/h2H2,1H3,(H,5,6)

Upstream product

• 105-39-5 chloroacetic acid ethyl ester 
• 74-89-5 methylamine 
• 79-04-9 chloroacetyl chloride 
• 112-41-4 1-dodecene 
• 50848-97-0 N-chloro-N-methylchloroacetamide 
• 593-51-1 methylamine hydrochloride 
• 3926-62-3 sodium monochloroacetic acid 
• 96-34-4 methyl chloroacetate 
• 115525-66-1 (E)-2-Chloro-4,4,5,5,6,6,7,7,7-nonafluoro-3-hydroxy-hept-2-enoic acid methyl ester 
• 115584-92-4 (E)-2-Chloro-4,4,5,5,6,6,6-heptafluoro-3-hydroxy-hex-2-enoic acid methyl ester 

Downstream Products

• 103096-30-6 benzimidazol-1-yl-acetic acid methylamide 
• 69061-04-7 8-<5-(4-fluorophenyl)-2-pentyl>-10-hydroxy-N,5,5-trimethyl-1,2,3,4-tetrahydro-5H-<1>benzopyrano<4,3-c>pyridine-2-acetamide 
• 42472-84-4 phtaloyl-glycyl-N-methylamid 
• 140676-68-2 {7-[4-(4-Fluoro-phenyl)-1-methyl-butyl]-10,10-dimethyl-3-methylcarbamoylmethyl-2,3,4,10-tetrahydro-1H-9-oxa-3-aza-phenanthren-5-yloxy}-acetic acid ethyl ester 
• 106231-50-9 2-(benzoyloxy)-N-methylacetamide 
• 113847-65-7 α-diphenylphosphino-N-methylacetamide 
• 256352-19-9 2-(4-benzyl-1-piperazinyl)-N-methylacetamide 
• 57235-84-4 1-methyl-5-chloromethyl-1,2,3,4-tetrazole 
• 203640-48-6 Z-L-Ala N-methylcarbamoylmethyl ester 
• 956427-90-0 tert-butyl [2-[(4-aminobenzoyl)amino]-4-(2-thienyl)phenyl][2-(methylamino)-2-oxoethyl]carbamate 
• 59721-19-6 N-methylcarbamoylmethyl-p-hydroxyphenylacetate 

Relevant articles and documents

Amide bond formation in aqueous solution: Direct coupling of metal carboxylate salts with ammonium salts at room temperature

Herein, we report a green, expeditious, and practically simple protocol for direct coupling of carboxylate salts and ammonium salts under ACN/H2O conditions at room temperature without the addition of tertiary amine bases. The water-soluble coupling reagent EDC·HCl is a key component in the reaction. The reaction runs smoothly with unsubstituted/substituted ammonium salts and provides a clean product without column chromatography. Our reaction tolerates both carboxylate (which are unstable in other forms) and amine salts (which are unstable/volatile when present in free form). We believe that the reported method could be used as an alternative and suitable method at the laboratory and industrial scales. This journal is

Method for preparing O, O-dimethyl-S-methylcarbamoylmethyl phosphorodithioate

The invention belongs to the technical field of pesticides, and particularly relates to a method for preparing O, O-dimethyl-S-methylcarbamoylmethyl phosphorodithioate. Chloroacetyl chloride and dimethyl phosphite are used as raw materials to prepare the O, O-dimethyl-S-methylcarbamoylmethyl phosphorodithioate for the first time, the product prepared by using the method is high in yield and purity, no waste liquid is generated in the preparation process, the preparation process is simple, and reaction mother liquor, such as the mother liquor in the step 1 and the step 3, does not need to be treated and can be recycled 6-8 times; while the yield of the product is further improved, the product keeps a high purity, and the quality of the product is ensured. By using the method, through optimization of a reaction system and selection of reaction details, the yield in the reaction in each step can be high. Besides, by using the method, after the reaction is completed, through simple aftertreatment steps, the water content of the obtained product can be as low as 0.032%, and the problem is solved that the product is decomposed due to high water content.

N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES

The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2,L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to compounds for use in methods of inhibiting the ATF4 (activating transcription factor 4) pathway and treatment of disorders associated therewith, such as e.g. cancer, neurodegenerative diseases and many other diseases, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Preferred compounds of the invention are N-(3-(2-(4-chlorophenoxy) acetamido)bicyclo[1.1.1]pentan-l-yl)-2-cyclobutane-l-carboxamide derivatives and related compounds.